Indivior PLC (NASDAQ:INDV) Sees Significant Increase in Short Interest

Indivior PLC (NASDAQ:INDV) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 10,322,427 shares, a growth of 57.5% from the December 15th total of 6,555,910 shares. Approximately 8.3% of the company’s stock are short sold. Based on an average daily volume of 3,623,093 shares, the short-interest ratio is currently 2.8 days. Based on an average daily volume of 3,623,093 shares, the short-interest ratio is currently 2.8 days. Approximately 8.3% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Morgan Stanley reaffirmed an “overweight” rating and issued a $36.00 price objective on shares of Indivior in a report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Indivior in a research note on Friday, October 31st. Northland Securities set a $40.00 price objective on shares of Indivior in a research note on Friday, October 31st. Finally, HC Wainwright raised their target price on shares of Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.57.

Insider Buying and Selling

In other news, Director Barbara Ryan purchased 775 shares of the stock in a transaction dated Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the acquisition, the director owned 1,963 shares of the company’s stock, valued at $69,470.57. The trade was a 65.24% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Mark Stejbach acquired 775 shares of Indivior stock in a transaction that occurred on Monday, January 5th. The shares were purchased at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the purchase, the director directly owned 16,847 shares of the company’s stock, valued at $596,215.33. The trade was a 4.82% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 4,871 shares of company stock worth $172,385 over the last quarter.

Hedge Funds Weigh In On Indivior

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Blue Trust Inc. increased its stake in shares of Indivior by 17.8% in the fourth quarter. Blue Trust Inc. now owns 4,859 shares of the company’s stock valued at $176,000 after buying an additional 733 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Indivior in the fourth quarter valued at approximately $448,000. Hennion & Walsh Asset Management Inc. raised its position in shares of Indivior by 43.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 317,600 shares of the company’s stock valued at $11,395,000 after acquiring an additional 96,177 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Indivior by 752.2% during the fourth quarter. SG Americas Securities LLC now owns 412,197 shares of the company’s stock worth $14,790,000 after purchasing an additional 363,829 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC bought a new position in Indivior during the fourth quarter worth about $312,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Price Performance

Indivior stock traded down $0.34 during trading hours on Friday, hitting $32.54. The company had a trading volume of 2,317,098 shares, compared to its average volume of 2,192,063. The firm’s fifty day moving average is $34.34 and its 200-day moving average is $26.56. Indivior has a fifty-two week low of $7.62 and a fifty-two week high of $38.00. The firm has a market capitalization of $4.07 billion, a P/E ratio of 35.37 and a beta of 0.75.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%.The company had revenue of $314.00 million during the quarter, compared to analysts’ expectations of $257.66 million. Analysts anticipate that Indivior will post 1.22 earnings per share for the current year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.